Vaccine Info

Redeeflu Influenza Vaccine

Authored by
Staff
Last reviewed
June 12, 2021
Share

Redeeflu Influenza Description

Redeeflu is a nasal vaccine candidate utilizing a proprietary M2 deleted, single replication (M2SR) influenza virus.

The M2 gene is essential for the influenza virus to spread in the patient and the deletion of the M2 gene restricts the virus to a single replication cycle in the host.

The M2SR vaccine contains vaccine viruses with a deletion in a portion of the M2 gene. M2SR viruses can infect cells, express the entire spectrum of influenza RNA and proteins, yet cannot produce any infectious virus particles. Thus, the M2SR vaccines do not shed infectious viruses and do not cause any pathological signs of infection. The M2SR viruses can be engineered to express the HA and neuraminidase antigens (NA) of any influenza virus and can be manufactured in cell lines that stably express the M2 protein.

The body recognizes M2SR as an influenza infection and activates its robust immune response, but because the virus can replicate only once, it cannot spread to other cells and cause symptoms of real influenza infection.

Redeeflu Influenza Indication

Redeeflu is indicated to prevent influenza

Redeeflu Influenza Dosage

Redeeflu is administered intranasally.

The RedeeFlu viruses can be engineered to express the HA and neuraminidase antigens (NA) of any influenza virus and can be manufactured in cell lines that stably express the M2 protein.

Redeeflu Influenza News

May 25, 2021 - FluGen Initiates NIH-Funded Trial of M2SR Flu Vaccine; First Study in Adults Up to Age 85

October 18, 2017 - FluGen Awarded $14.4 million by the Department of Defense to Test Universal Flu Vaccine Against Mismatched Strains. Under the three-year award, FluGen will conduct two challenge studies with RedeeFlu.

Redeeflu Influenza Clinical Trials

Redeeflu influenza vaccine candidate continues to be tested in clinical trials.